Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE +
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Policy
July 20, 2021 05:17 PM

Health systems' rare rejection of Alzheimer's drug sparks questions about FDA approvals

Mari Devereaux
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    An older patient talking to a doctor
    Getty Images

    While heightened controversy and discussion is rare for Food and Drug Administration-approved drugs, outcry over the Alzheimer's drug Aduhelm could lead to a broader conversation about the approval process and what patients and providers are looking for with value-based care.

    The medical community's reaction to Aduhelm has been especially uncommon with independent review boards stating that they wouldn't have approved the drug and providers declining to administer it, said Rick Kes, healthcare partner at RSM.

    "The last time that there was a lot of controversy surrounding a specific drug and the process that it went through—with the exception of the COVID-19 vaccine—you're probably thinking back to drugs to treat HIV and AIDS," Kes said.

    Around 50 new FDA-approved drugs hit the market in 2019 and 2020, down from a peak of 59 novel drugs in 2018, according to a Statista study. Thousands of medications are in development nationwide and some companies are weighing the pros and cons of getting FDA approval for their products.

    Ultimately, patients want drugs to be approved that will help them live longer and better, said Andrew Hertler, an oncologist and chief medical officer at New Century Health.

    "Unfortunately, our current drug approval process does not accomplish that," Hertler said. "We've got a system that rewards marginal improvement, doesn't drive the studies we need [in order] to see comparative effectiveness, and really doesn't deliver the results that we're looking for."

    Although the Center for Drug Evaluation and Research's accelerated approval process was put in place to quickly get drugs to patients with life threatening diseases, it can incentivize speed over quality, he said.

    Only 6% of drugs that have been approved to treat cancer looked at quality of life as part of their clinical trials, according to Hertler. Clinical trials also rarely compare a drug against the standard of care, and many drug approvals for life-threatening conditions don't have any increase in patient survival rates.

    As more payers delve into value-base care arrangements that incentivize positive drug outcomes, it could lead to questions over whether the payments are advancing healthcare.

    It is more common for health systems to not cover medications if there are better alternatives available, said Antonio Ciaccia, CEO of 46brooklyn Research. He said it is unusual that care providers would loudly and publicly reject a drug, in the case of Aduhelm. Particularly a drug that currently has no alternative.

    Aduhelm is the first new Alzhiemer's treatment approved by the FDA in 18 years, something notable for the more than 6 million Americans who live with the disease. Still, due process is necessary to determine its side effects, benefits and whether or not it is an effective treatment, Kes said.

    FDA could achieve this by holding manufacturers to completing comparative effectiveness studies and better enforce the rules already in place. according to Hertler.

    "You could put some incentive behind that by not allowing companies to charge market price for drugs … until the studies are done," Hertler said.

    But the concerns over Aduhelm have also shaken public trust in FDA's ability to keep people safe, Ciaccia said.

    "I am a little concerned that, regardless of whether [the FDA was] right or wrong, this issue of the approval process not being trusted generally could have a cascading effect [on] future approvals of the agency as well," Ciaccia said.

    In this way, providers have some power and influence by publicly stating that a drug is not good and should not be used if there are other choices available, Hertler said.

    "You don't have to use a drug just because it's marketed and it's new and there's publicity around it," Hertler said. "[Especially] if the data and the evidence don't support that this is a significant benefit over what we already have out there."

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Copy of 101920-news-insurance-ok_WEB_i.jpg
    CMS issues Medicare Advantage, Part D 2024 payment policy notice
    PHE ending
    What the end of the federal COVID-19 emergency means for healthcare
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE +
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing